|
|
||||||||||
|
J Am Coll Cardiol, 2008; 51:1910-1911, doi:10.1016/j.jacc.2008.02.037 © 2008 by the American College of Cardiology Foundation |
* Libin Cardiovascular Institute of Alberta, 3330 Hospital Drive NW; Room G208, Calgary, Alberta, Canada T2N 4N1 (Email: exner{at}ucalgary.ca).
Antiarrhythmic drug use was uncommon in the REFINE study; 6 patients (2%) received amiodarone and 3 (1%) received sotalol. Antiarrhythmic drug use was similar in patients who did versus did not suffer the primary outcome (p = 0.2) and was not associated with an increased risk of the primary outcome (HR 1.6, 95% CI 0.2 to 12.5; p = 0.6). As with NSVT, the association of impaired heart rate turbulence plus abnormal repolarization alternans with an increased risk of the primary outcome was not altered when antiarrhythmic drug usage was adjusted for (HR 5.4, 95% CI 2.3 to 12.6; p < 0.0001).
We did not evaluate distal embolization in the REFINE study, because we sought to assess markers of long-term risk. Multiple studies have shown that distal embolization impacts short-term 30- to 60-day risk of adverse clinical outcomes and not long-term 4-year risk (2,3). The strong association between impaired heart rate turbulence plus abnormal repolarization alternans with an increased risk of the primary outcome was not altered when change in ejection fraction over the initial 2 months after MI, a surrogate of successful reperfusion, was adjusted for (HR 5.1, 95% CI 2.2 to 11.9; p < 0.0001).
In conclusion, the concerns of Drs. Goyal and Punnam do not detract from our findings. As clearly demonstrated (1), the combination of impaired heart rate turbulence plus abnormal repolarization alternans assessed in the nonacute post-MI period reliably predicts the long-term risk of serious outcomes. Thus, we believe these markers are the right indicators.
| References |
|---|
|
|
|---|
Related articles in JACC:
| ||||||||||||||||||||||||||||||||||||||||||
| HOME | SUBSCRIPTIONS | CURRENT ISSUE | PAST ISSUES | CARDIOSOURCE | SEARCH | HELP | FEEDBACK |